The company is actively supporting customer reshoring, which is first targeted in its CDMO business and then more broadly in bioproduction and analytical instruments.
The program will leverage the CDMO’s microbial manufacturing network across its Heidelberg, Germany and Chiba, Japan facilities for clinical trial supply.
The agreement supports a$260 million national vaccine localization initiative, with SK bioscience’s varicella vaccine selected as the initial product for technology transfer.
Learn about the latest pharma manufacturing facility trends from our expert panelists, including digital twins, real-time process analytics and innovations in AI and machine learning.
